scholarly journals Mouse multiple myeloma (MM) model with constitutive IL-6 signal transducer (IL-6ST; gp130; CD130) expression

2014 ◽  
Vol 7 (47) ◽  
pp. 1392-1392
Keyword(s):  
Multiple Myeloma ◽  
Signal Transducer

scholarly journals HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

2021 ◽  
Vol 22 (3) ◽  
pp. 1341
Author(s):  
Sang Wu Lee ◽  
Soo-Keun Yeon ◽  
Go Woon Kim ◽  
Dong Hoon Lee ◽  
Yu Hyun Jeon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Nuclear Factor Kappa B ◽  
Selective Inhibitor ◽  
Signal Transducer ◽  
Histone Deacetylase 6 ◽  
Cell Growth Inhibition ◽  
Cancer Cell Growth ◽  
Extracellular Signal ◽  
Hdac6 Inhibitor ◽  
Transcription 3

Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 significantly decreases the activation of BTZ-resistant markers, such as extracellular signal-regulated kinases (ERK) and nuclear factor kappa B (NF-κB), in acquired BTZ-resistant MM cells. Combination treatment of A452 and BTZ or carfilzomib (CFZ) synergistically reduces BTZ-resistant markers. Additionally, A452 synergizes with BTZ or CFZ to inhibit the activation of NF-κB and signal transducer and activator of transcription 3 (STAT3), resulting in decreased expressions of low-molecular-mass polypeptide 2 (LMP2) and LMP7. Furthermore, combining A452 with BTZ or CFZ leads to synergistic cancer cell growth inhibition, viability decreases, and apoptosis induction in the BTZ-resistant MM cells. Overall, the synergistic effect of A452 with CFZ is more potent than that of A452 with BTZ in BTZ-resistant U266 cells. Thus, our findings reveal the HDAC6-selective inhibitor as a promising therapy for BTZ-chemoresistant MM.

Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells

2011 ◽  
Vol 112 (6) ◽  
pp. 1552-1562 ◽  
Author(s):  
Jang Choon Lee ◽  
Kwang Seok Ahn ◽  
Soo-Jin Jeong ◽  
Ji Hoon Jung ◽  
Tae-Rin Kwon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Signal Transducer ◽  
Myeloma Cells ◽  
Induced Apoptosis ◽  
Transcription 3

scholarly journals Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma

Biomolecules ◽  
2019 ◽  
Vol 10 (1) ◽  
pp. 23 ◽  
Author(s):  
Min Hee Yang ◽  
Sang Hoon Jung ◽  
Arunachalam Chinnathambi ◽  
Tahani Awad Alahmadi ◽  
Sulaiman Ali Alharbi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Therapeutic Strategy ◽  
Tyrosine Phosphatase ◽  
Signaling Cascade ◽  
Signal Transducer ◽  
Stat3 Signaling ◽  
Anti Cancer ◽  
Prostate Cancers ◽  
Apoptotic Effects ◽  
Transcription 3

Daidzin (DDZ) extracted from Pueraria lobate (Fabaceae) is a widely known phytoestrogen. DDZ can display anti-cancer activities against breast and prostate cancers, but its anti-oncogenic actions in multiple myeloma (MM) cells have not been studied. The signal transducer and activator of transcription 3 (STAT3) can control key processes including proliferation, differentiation, and survival in MM cells. Here, we noted that DDZ abrogated STAT3 activation (both constitutive as well as inducible) at Tyr705 and Ser727 in MM cells. Additionally, DDZ mitigated the phosphorylation of STAT3 upstream Janus-activated kinases (JAK1/2) and c-Src kinases. Pervanadate (tyrosine phosphatase blocker) exposure altered the DDZ-induced inhibition of STAT3 activation, thus affecting the action of this phytoestrogen on apoptosis. Moreover, DDZ impeded proliferation and augmented the apoptotic effects of bortezomib (Bor) in MM cells. Overall, the data indicate that DDZ may act as a potent suppressor of STAT3 signaling cascade, and the co-treatment of DDZ and Bor could be a promising therapeutic strategy, specifically in MM.

Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains ofJAK1

2013 ◽  
Vol 55 (5) ◽  
pp. 1176-1180
Author(s):  
Fernanda C. Corbi ◽  
Mariana Bleker de Oliveira ◽  
Vania M. Morelli ◽  
Sang W. Han ◽  
Jean-Christophe Renauld ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Point Mutations ◽  
Janus Kinase ◽  
Signal Transducer

scholarly journals Analysis of Signal Transducer and Activator of Transcription 3 (Stat 3) Pathway in Multiple Myeloma

2003 ◽  
Vol 162 (5) ◽  
pp. 1449-1461 ◽  
Author(s):  
Leticia Quintanilla-Martinez ◽  
Marcus Kremer ◽  
Katja Specht ◽  
Julia Calzada-Wack ◽  
Michaela Nathrath ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Signal Transducer ◽  
Transcription 3

Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells

2011 ◽  
Vol 654 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Sun-Hee Kim ◽  
Kwang Seok Ahn ◽  
Soo-Jin Jeong ◽  
Tae-Rin Kwon ◽  
Ji Hoon Jung ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Signal Transducer ◽  
Myeloma Cells ◽  
Icariside Ii ◽  
Induced Apoptosis ◽  
Transcription 3

scholarly journals Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Blood ◽  
2007 ◽  
Vol 110 (4) ◽  
pp. 1330-1333 ◽  
Author(s):  
Dennis Löffler ◽  
Katja Brocke-Heidrich ◽  
Gabriele Pfeifer ◽  
Claudia Stocsits ◽  
Jörg Hackermüller ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Strong Evidence ◽  
Interleukin 6 ◽  
Binding Sites ◽  
Signal Transducer ◽  
Gene Encoding ◽  
Oncogenic Potential ◽  
Myeloma Cells ◽  
Survival And Growth ◽  
Transcription 3

Abstract Signal transducer and activator of transcription 3 (Stat3) is implicated in the pathogenesis of many malignancies and essential for IL-6–dependent survival and growth of multiple myeloma cells. Here, we demonstrate that the gene encoding oncogenic microRNA-21 (miR-21) is controlled by an upstream enhancer containing 2 Stat3 binding sites strictly conserved since the first observed evolutionary appearance of miR-21 and Stat3. MiR-21 induction by IL-6 was strictly Stat3 dependent. Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3.

Sign in / Sign up

Export Citation Format

Share Document